NEORAL by Novartis is clinical pharmacology cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. Approved for organ rejection in kidney, liver, heart allogeneic transplants and 2 more indications. First approved in 1997.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
NEORAL (cyclosporine) is a potent immunosuppressive small molecule that selectively inhibits T-lymphocyte activation by blocking interleukin-2 production and lymphokine release. It is indicated for prevention of organ rejection in kidney, liver, and heart allogeneic transplants, as well as for rheumatoid arthritis and severe psoriasis unresponsive to other therapies. The drug works through specific and reversible inhibition of immunocompetent lymphocytes in the cell cycle, with preferential targeting of T-helper cells.
Product approaching loss of exclusivity with minimal current market spending ($1M reported); brand team is likely in defensive or maintenance mode with reduced commercial expansion opportunities.
CLINICAL PHARMACOLOGY Cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. Cyclosporine has been demonstrated to suppress some humoral immunity and to a…
Worked on NEORAL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation
Working on NEORAL in its LOE-approaching phase offers limited career growth but provides deep expertise in complex immunosuppression and transplant medicine. Roles focus on defending market share, managing generic transition, and ensuring product supply/compliance rather than driving expansion.